News :

In the future, major structures like bridges, dams, tunnels, railroad tracks, oceangoing vessels, cooling towers, and wind-turbine blades could be instrumented with Morphosense’s MEMS accelerometer networks. Morphosense is a Leti spinoff founded in mid-2016 to develop a precision structural-health monitoring system leveraging ten years of R&D. The system, which consists of sensors mounted at strategic […] >>

Delivery of the six-level, 12,800 sq. m photonics platform was originally scheduled for early November, but has been pushed back to January due to construction delays and the results of certain tests. The contractor that won the bid will have to put additional resources on the job to complete construction. The CEA has set up […] >>

In the future, diabetics suffering from neuropathy (in their hands and feet, for example) could benefit from a new drug called atexakin, which regenerates damaged nerve fibers. Switzerland’s Relief Therapeutics Holding AG recently signed an agreement with Merck to develop, manufacture, and commercialize the drug. Merck then turned to Grenoble’s PX’Therapeutics to develop an efficient […] >>

Enerbee, a two-year-old startup specializing in micro-generators that harvest energy from movement, has turned a corner in its development. The company will now leverage its proprietary technology to develop self-powering connected ventilation systems, ultimately carving out a position on a high-added-value, IoT-related market. Enerbee will present a prototype at CES* Las Vegas in January. The […] >>

Fluoptics has carved out the top slot on Europe’s real-time fluorescence imaging solutions market. The company has implemented more than 100 of its Fluobeam® non-invasive surgical-assistance systems in sixteen countries. Fluoptics’ technology is currently the only one in the world capable of generating images of parathyroid glands using light during tricky thyroid surgery—ultimately improving patient […] >>